Hyderabad: Yashoda Hospitals launched the Revolutionary Technology ‘HPV DNA test’ for early diagnosis of cervical cancer (lower part of the uterus) in women. According to Dr. Shanta Kumari, senior gynecologist and president of FOGSI, the ‘HPV DNA TEST’ is more sensitive than the current PAP smear test, which is often used to recognize cervical cancer.
Dr Lalitha Reddy, vice president of Yashoda Group, expressed that, in districts and remote regions of the State, the screening kits are available with doctors so that patients are not required to travel far to give samples. Samples taken from different locations of the State would be analyzed centrally in Yashoda Hospital Laboratory, and the patients and doctors would have the reports locally.
Approximately 250 female delegates who are experts in their fields attended the event to raise awareness of the high-risk HPV DNA test. Cervical cancer is the most important cancers and cancer-related deaths among women worldwide, India alone accounting for almost one-quarter of the risk of cervical cancer.
Dr. Pavan Gorukanti, Director of Yashoda Hospitals, said HPV (Human Papilloma Virus) would be one of the main risk factors for developing cervical cancer. More than 90% of cervical cancers worldwide have been associated with the presence of HPV.
Roche Diagnostics India and Yashoda Hospitals are collaborating to announce the new diagnostic Technique. Dr. Shravan Subramanyam, Managing Director of India and Neighbouring countries, Roche Diagnostics, said Cervical cancer is entirely preventable, and it must be immediately diagnosed. Effective and exact screening is important to save women’s lives.
The Additional Director General of Police, Abhilasha Bisht, advised women to take their health more seriously and improve health and fitness.
